Optimization of the Time and Dosage of Vemurafenib in BRAF Positive Juvenile Patients With Refractory Histiocytosis
Status:
Recruiting
Trial end date:
2026-06-23
Target enrollment:
Participant gender:
Summary
Prospective, interventional, open, randomized, single-center, non-commercial clinical trial
to optimize treatment and dosage of vemurafenib in juvenile patients with histiocytosis
resistant to conventional therapy and in whom the BRAF gene mutation has been found.
Phase:
Phase 2
Details
Lead Sponsor:
Anna Raciborska
Collaborators:
Łukasiewicz Research Network Maria Sklodowska-Curie Institute - Oncology Center Wrocław University of Environmental and Life Sciences